Abstract:Background Duchenne muscular dystrophy incurs nearly universal dilated cardiomyopathy by the third decade of life, preceded by myocardial damage and impaired left ventricular strain by cardiac magnetic resonance. It has been shown that (1) mineralocorticoid receptor antagonist therapy with spironolactone attenuated damage while maintaining function when given early in a mouse model and (2) low‐dose eplerenone stabilized left ventricular strain in boys with Duchenne muscular dystrophy and evident myocardial damage but preserved ejection fraction. We hypothesized that moderate‐dose spironolactone versus eplerenone would provide similar cardioprotection in this first head‐to‐head randomized trial of available mineralocorticoid receptor antagonists, the AIDMD (Aldosterone Inhibition in Duchenne Muscular Dystrophy) trial. Methods and Results This was a multicenter, double‐blind, randomized, noninferiority trial. Subjects were randomized to eplerenone, 50 mg, or spironolactone, 50 mg, orally once daily for 12 months. The primary outcome was change in left ventricular systolic strain at 12 months. Among 52 enrolled male subjects, aged 14 (interquartile range, 12–18) years, spironolactone was noninferior to eplerenone (∆strain, 0.4 [interquartile range, −0.4 to 0.6] versus 0.2 [interquartile range, −0.2 to 0.7]; P =0.542). Renal and pulmonary function remained stable in both groups, and no subjects experienced serious hyperkalemia. Infrequent adverse events included gynecomastia in one subject in the spironolactone arm and facial rash in one subject in the eplerenone arm. Conclusions In boys with Duchenne muscular dystrophy and preserved left ventricular ejection fraction, spironolactone added to background therapy is noninferior to eplerenone in preserving contractile function. These findings support early mineralocorticoid receptor antagonist therapy as effective and safe in a genetic disease with high cardiomyopathy risk. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT02354352. Clinical Perspective What Is New? In this first head‐to‐head study of available mineralocorticoid receptor antagonist drugs, spironolactone was noninferior to eplerenone in preserving cardiac contractility in boys with Duchenne muscular dystrophy. What Are the Clinical Implications? In patients at high genetic risk of dilated cardiomyopathy, initiation of a mineralocorticoid receptor antagonist while ejection fraction is preserved may stabilize cardiac function and attenuate progressive myocardial damage. Introduction Duchenne muscular dystrophy (DMD), the most common severe form of muscular dystrophy, is an X‐linked disorder in which the sarcolemmal protein dystrophin is effectively absent. Male patients with DMD typically die in the third and fourth decades of life of cardiopulmonary disease. 1 Mouse models of DMD, autopsy data, and in vivo human studies using cardiac magnetic resonance (CMR)–based late gadolinium enhancement (LGE) imaging have all shown that progressive myocardial damage occurs well before left ventricular ejection fraction (LVEF) becomes abnormal. 2 Decline in cardiac function portends complications, such as heart failure, arrhythmias, and sudden death. Patients with DMD do not manifest clinical signs of cardiomyopathy until LV dysfunction and myocardial fibrosis are advanced. Thus, sensitive biomarkers are required to afford timely therapy that preserves function and prevents complications. Echocardiography is widely used to assess LV function in patients with DMD; reproducibility is impacted by acoustic window that may be limited, particularly as body habitus changes over time, reducing its appeal for rare disease clinical trials of modest sample size. 3 CMR with LGE offers high reproducibility and identifies myocardial injury before decline in EF is apparent. 4 , 5 LV strain by CMR is a sensitive and early marker of LV systolic dysfunction in DMD and is measurably abnormal before EF declines. 6 < -Abstract Truncated-

High-throughput proteomic analysis unveils metabolic and mitochondrial signaling rewiring by chronic ivabradine treatment in duchenne muscular dystrophy

Ivabradine ameliorates cardiomyopathy progression in a Duchenne muscular dystrophy model rat

Ivabradine Promotes Angiogenesis and Reduces Cardiac Hypertrophy in Mice with Myocardial Infarction.

Ivabradine prevents doxorubicin-induced cardiotoxicity via attenuating mitochondrial dysfunction and mitochondrial dynamic imbalance in H9C2 cells and rats

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.

Ivabradine Alleviates Experimental Autoimmune Myocarditis-Mediated Myocardial Injury

Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin-Deficient D2.B10-Dmd mdx /J Mouse

Chronic Dantrolene Treatment Attenuates Cardiac Dysfunction and Reduces Atrial Fibrillation Inducibility in a Rat Myocardial Infarction Heart Failure Model

I(f) Current Channel Inhibitor (ivabradine) Deserves Cardioprotective Effect Via Down-Regulating the Expression of Matrix Metalloproteinase (MMP)-2 and Attenuating Apoptosis in Diabetic Mice.

Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice.

Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model

Nifedipine Treatment Reduces Resting Calcium Concentration, Oxidative and Apoptotic Gene Expression, and Improves Muscle Function in Dystrophic mdx Mice

Inhibition of JNK and P38 MAPK‐mediated Inflammation and Apoptosis by Ivabradine Improves Cardiac Function in Streptozotocin‐induced Diabetic Cardiomyopathy

Ivabradine protects rats against myocardial infarction through reinforcing autophagy via inhibiting PI3K/AKT/mTOR/p70S6K pathway

VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism

Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy

Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response

Hyperpolarization‐activated cyclic nucleotide‐gated channel inhibitor in myocardial infarction: Potential benefits beyond heart rate modulation

Effects of ivabradine hydrochloride combined with trimetazidine on myocardial fibrosis in rats with chronic heart failure

Increased SERCA2a activity underlies the mechanism of positive inotropic effect of ivabradine.

Activation of the PP2A Catalytic Subunit by Ivabradine Attenuates the Development of Diabetic Cardiomyopathy.